---

Related Articles:

Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).

2014-12-01

[Am. J. Cardiol. 114(11) , 1713-21, (2014)]

Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.

2015-01-01

[J. Am. Soc. Nephrol. 26(1) , 39-47, (2015)]

Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

2013-01-01

[Circ. Heart Fail. 6(1) , 47-52, (2013)]

Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.

2013-03-01

[Future Cardiol. 9(2) , 163-76, (2013)]

Tolvaptan: a new therapeutic agent.

2011-05-01

[Rev. Recent Clin. Trials 6(2) , 177-88, (2011)]